- Home
- SERA
as 06-30-2025 11:34am EST
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
| Founded: | 2008 | Country: | United States |
| Employees: | 64 | City: | SALT LAKE CITY |
| Market Cap: | 70.4M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 803.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.37 - $9.13 | Next Earning Date: | 08-06-2025 |
| Revenue: | $115,000 | Revenue Growth: | -44.17% |
| Revenue Growth (this year): | 390.13% | Revenue Growth (next year): | 440.54% |
Stock Insider Trading Activity of Sera Prognostics Inc. (SERA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kearney Paul | SERA | Chief Data Officer | Jun 10 '25 | Sell | $1.48 | 1,311 | $1,940.28 | 195,400 | |
| Jackson Benjamin | SERA | General Counsel | Jun 10 '25 | Sell | $1.48 | 965 | $1,428.20 | 134,198 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Jun 10 '25 | Sell | $1.48 | 667 | $987.16 | 114,539 | |
| Lindgardt Zhenya | SERA | Chief Executive Officer | Jun 9 '25 | Sell | $1.46 | 26,386 | $37,899.18 | 840,865 | |
| Aerts Austin | SERA | Chief Financial Officer | Jun 9 '25 | Sell | $1.46 | 6,680 | $9,599.65 | 297,593 | |
| Mirza Mansoor Raza | SERA | Director | Jun 5 '25 | Sell | $1.58 | 107 | $169.06 | 59,161 | |
| Boniface John J. | SERA | Chief Scientific Officer | May 8 '25 | Sell | $2.44 | 5,132 | $12,522.08 | 165,718 | |
| Lindgardt Zhenya | SERA | Chief Executive Officer | May 8 '25 | Sell | $2.44 | 9,406 | $22,950.64 | 840,865 | |
| Kearney Paul | SERA | Chief Data Officer | May 8 '25 | Sell | $2.44 | 7,089 | $17,297.16 | 195,400 | |
| Jackson Benjamin | SERA | General Counsel | May 8 '25 | Sell | $2.44 | 7,084 | $17,284.96 | 134,198 |
Latest Sera Prognostics Inc. News
SERA Breaking Stock News: Dive into SERA Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Investopedia
a month ago
Ulta Stock Jumps as Beauty Product Spending Continues
GlobeNewswire
a month ago
Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy
GlobeNewswire
a month ago
Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
Benzinga
a month ago
Northrop Grumman Raises $1 Billion Via Debt
GlobeNewswire
a month ago
Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy
GlobeNewswire
a month ago
TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast
GlobeNewswire
a month ago
The York Water Company Files a Rate Request Based on $145 Million in Investment
Compare SERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SERA Sera Prognostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.